Literature DB >> 19454589

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.

Manfredi Rizzo1, Kaspar Berneis, Martin Hersberger, Ilenia Pepe, Gaetana Di Fede, Giovam Battista Rini, Giatgen A Spinas, Enrico Carmina.   

Abstract

BACKGROUND: Dyslipidemia is common in women with polycystic ovary syndrome (PCOS) but its prevalence in different PCOS phenotypes is still largely unknown.
METHODS: We measured plasma lipids and lipoproteins in 35 anovulatory PCOS (age: 25 +/- 6 years, BMI: 28 +/- 6 kg/m(2)), 15 ovulatory PCOS (age: 30 +/- 6 years, BMI: 25 +/- 3 kg/m(2)) and 27 healthy women (controls) age- and BMI-matched with ovulatory PCOS. PCOS was diagnosed by the presence of clinical or biologic hyperandrogenism associated with chronic anovulation and/or polycystic ovaries at ultrasound. In women with normal menses chronic anovulation was indicated by low serum progesterone levels (<9.54 nmol/l) during midluteal phase (days 21-24) in two consecutive menstrual cycles.
RESULTS: Total cholesterol, triglycerides and low-density lipoprotein (LDL)-cholesterol levels increased and high-density lipoprotein (HDL)-cholesterol decreased from controls to ovulatory and then to anovulatory PCOS (all P < 0.05). Levels of lipoprotein(a) (Lp(a)) and small, dense LDL increased (P < 0.0001 for both) and LDL size reduced (P < 0.005) between groups. Insulin resistance (by HOMA) showed a positive correlation with triglycerides and small, dense LDL and an inverse correlation with HDL-cholesterol and LDL size (P < 0.05 for all) in both PCOS phenotypes. No significant correlations were found with testosterone levels. At multivariate analysis, insulin resistance was independently associated with HDL-cholesterol and small, dense LDL in both PCOS phenotypes and with triglyceride concentrations in ovulatory PCOS only.
CONCLUSIONS: Women with ovulatory PCOS showed milder forms of atherogenic dyslipidemia than anovulatory PCOS and this seemed to be related to the extent of insulin resistance. Future prospective studies are needed to assess the relative contribution of such alterations on cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454589     DOI: 10.1093/humrep/dep121

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  23 in total

1.  Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.

Authors:  M Rizzo; R A Longo; E Guastella; G B Rini; E Carmina
Journal:  J Endocrinol Invest       Date:  2010-10-15       Impact factor: 4.256

2.  Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk.

Authors:  E Gourgari; M Lodish; R Shamburek; M Keil; R Wesley; M Walter; M Sampson; S Bernstein; D Khurana; C Lyssikatos; S Ten; A Dobs; A T Remaley; C A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-09-15       Impact factor: 5.958

Review 3.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 4.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

Review 5.  Polycystic ovary syndrome: do endocrine-disrupting chemicals play a role?

Authors:  Emily S Barrett; Marissa Sobolewski
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

6.  Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation.

Authors:  Sunni L Mumford; Enrique F Schisterman; Anna Maria Siega-Riz; Audrey J Gaskins; Anne Z Steiner; Julie L Daniels; Andrew F Olshan; Mary L Hediger; Kathleen Hovey; Jean Wactawski-Wende; Maurizio Trevisan; Michael S Bloom
Journal:  Hum Reprod       Date:  2010-11-28       Impact factor: 6.918

7.  Metabolic and carbohydrate characteristics of different phenotypes of polycystic ovary syndrome.

Authors:  Ebru Çelik; Ilgın Türkçüoğlu; Barış Ata; Abdullah Karaer; Pınar Kırıcı; Sevil Eraslan; Çağatay Taşkapan; Bülent Berker
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-12-01

8.  Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.

Authors:  Andrea Roe; Jennifer Hillman; Samantha Butts; Mathew Smith; Daniel Rader; Martin Playford; Nehal N Mehta; Anuja Dokras
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

9.  C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome.

Authors:  Nilgün Güdücü; Herman Işçi; Alin Başgül Yiğiter; Ilkkan Dünder
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-12-01

10.  Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS).

Authors:  Susanne Tan; André Scherag; Onno Eilard Janssen; Susanne Hahn; Harald Lahner; Tiina Dietz; Susann Scherag; Harald Grallert; Carla Ivane Ganz Vogel; Rainer Kimmig; Thomas Illig; Klaus Mann; Johannes Hebebrand; Anke Hinney
Journal:  BMC Med Genet       Date:  2010-01-21       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.